Nachrichten zu TransCode Therapeutics

Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX18.969,23+1,18 %

Gold2.587,10+0,01 %

Öl (Brent)74,82+2,79 %

Dow Jones42.034,91+1,31 %

US Tech 10019.838,04+2,59 %

EUR/USD1,11586-0,03 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

TransCode Therapeutics Aktie

Aktie

ISIN: US89357L1052 WKN: A3EZZQ SYM: RNAZ Land Flagge US

USA

0,2691

USD

0,00 %

0,0000 USD

Letzter Kurs 23.05.23 Nasdaq

Geldkurs

22.05.23

0,2650

USD

4.400 STK

Briefkurs

22.05.23

0,2760

USD

100 STK

TransCode Therapeutics Aktie kaufen

Neueste Nachrichten

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate 17.09.24 · globenewswire · TransCode Therapeutics
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer 10.09.24 · globenewswire · TransCode Therapeutics
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate 05.09.24 · globenewswire · TransCode Therapeutics
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation 15.08.24 · globenewswire · TransCode Therapeutics
TransCode Therapeutics, Inc. Announces Closing of Public Offering 24.07.24 · globenewswire · TransCode Therapeutics
TransCode Therapeutics, Inc. Announces Pricing of Public Offering 23.07.24 · globenewswire · TransCode Therapeutics
TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock 22.07.24 · globenewswire · TransCode Therapeutics
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements 10.06.24 · globenewswire · TransCode Therapeutics
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138 29.05.24 · globenewswire · TransCode Therapeutics
TransCode Therapeutics Open Letter to Shareholders 13.05.24 · globenewswire · TransCode Therapeutics
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors 15.04.24 · globenewswire · TransCode Therapeutics
TransCode Therapeutics Reports 2023 Results; Provides Business Update 03.04.24 · globenewswire · TransCode Therapeutics

1
2
…
3

Meistgelesen

7 Tage
30 Tage
12 Monate

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with ... 248 Leser

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead ... 348 Leser
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with ... 248 Leser
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing ... 156 Leser

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing ... 748 Leser
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead ... 348 Leser
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress 264 Leser
TransCode Therapeutics Reports 2023 Results; Provides Business Update 252 Leser
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with ... 248 Leser
TransCode Therapeutics Open Letter to Shareholders 236 Leser
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology ... 216 Leser
TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with ... 196 Leser
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer 192 Leser
TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its ... 180 Leser